In vivo efficacy of ceftaroline fosamil in a methicillin-resistant Panton-Valentine leukocidin-producing Staphylococcus aureus rabbit pneumonia model

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 4, 2014, Pages 1855-1861

  Croisier Bertin, Delphine ^a   Hayez, Davy ^a   Da Silva, Sonia ^a   Labrousse, Delphine ^a   Biek, Donald ^b   Badiou, Cedric ^c   Dumitrescu, Oana ^c   Guerard, Pascal ^d   Charles, Pierre Emmanuel ^e   Piroth, Lionel ^f   Lina, Gerard ^c   Vandenesch, Francois ^c   Chavanet, Pascal ^a,f  

^a Vivexia Laboratory   (France)

^b Cerexa Inc   (United States)

^c CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE   (France)

^d Laboratoire de Pharmacologie Toxicologie   (France)

^e UNIVERSITÉ DE BOURGOGNE   (France)

^f DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAROLINE FOSAMIL; CLINDAMYCIN; LINEZOLID; PANTON VALENTINE LEUKOCIDIN; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; BACTERIAL LOAD; CLONE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IN VIVO STUDY; LUNG; LUNG INJURY; MALE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; NONHUMAN; PRIORITY JOURNAL; SPLEEN;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL TOXINS; CEPHALOSPORINS; EXOTOXINS; LEUKOCIDINS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PNEUMONIA; RABBITS; STAPHYLOCOCCAL INFECTIONS;

EID: 84896991118     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01707-13     Document Type: Article

References (43)

1. O'Hara FP, Amrine-Madsen H, Mera RM, Brown ML, Close NM, Suaya JA, Acosta CJ. 2012. Molecular characterization of Staphylococcus aureus in the United States 2004-2008 reveals the rapid expansion of USA300 among inpatients and outpatients. Microb. Drug Resist. 18:555-561. http://dx.doi.org/10.1089/mdr. 2012.0056.
2. Hidron AI, Low CE, Honig EG, Blumberg HM. 2009. Emergence of community-acquired meticillin-resistant Staphylococcus aureus strain USA300 as a cause of necrotising community-onset pneumonia. Lancet Infect. Dis. 9:384-392. http://dx.doi.org/10.1016/S1473-3099(09)70133-1.
3. Wunderink RG. 2013. How important is methicillin-resistant Staphylococcus aureus as a cause of community-acquired pneumonia and what is best antimicrobial therapy? Infect. Dis. Clin. North Am. 27:177-188. http://dx.doi.org/10.1016/j.idc.2012.11.006.
4. King MD, Humphrey BJ, Wang YF, Kourbatova EV, Ray SM, Blumberg HM. 2006. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA300 clone as the predominant cause of skin and soft-tissue infections. Ann. Intern. Med. 144:309-317. http://dx.doi.org/10.7326/0003-4819-144-5-200603070- 00005. (Pubitemid 46768185)
5. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, Craig AS, Zell ER, Fosheim GE, McDougal LK, Carey RB, Fridkin SK, Active Bacterial Core surveillance (ABCs) MRSA Investigators. 2007. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298:1763-1771. http://dx.doi.org/10.1001/ jama.298.15.1763.
6. Richter SS, Heilmann KP, Dohrn CL, Riahi F, Costello AJ, Kroeger JS, Biek D, Critchley IA, Diekema DJ, Doern GV. 2011. Activity of ceftaroline and epidemiologic trends in Staphylococcus aureus isolates collected from 43 medical centers in the United States in 2009. Antimicrob. Agents Chemother. 55:4154-4160. http://dx.doi.org/10.1128/AAC.00315-11.
7. Tenover FC, Goering RV. 2009. Methicillin-resistant Staphylococcus aureus strain USA300: origin and epidemiology. J. Antimicrob. Chemother. 64:441-446. http://dx.doi.org/10.1093/jac/dkp241.
8. Marchese A, Gualco L, Maioli E, Debbia E. 2009. Molecular analysis and susceptibility patterns of meticillin-resistant Staphylococcus aureus (MRSA) strains circulating in the community in the Ligurian area, a northern region of Italy: emergence of USA300 and EMRSA-15 clones. Int. J. Antimicrob. Agents 34:424-428. http://dx.doi.org/10.1016/j.ijantimicag.2009.06.016.
9. Schaumburg F, Köck R, Mellmann A, Richter L, Hasenberg F, Kriegeskorte A, Friedrich AW, Gatermann S, Peters G, von Eiff C, Becker K. 2012. Population dynamics among methicillin-resistant Staphylococcus aureus isolates in Germany during a 6-year period. J. Clin. Microbiol. 50:3186-3192. http://dx.doi.org/10.1128/JCM.01174-12.
10. Diep BA, Chan L, Tattevin P, Kajikawa O, Martin TR, Basuino L, Mai TT, Marbach H, Braughton KR, Whitney AR, Gardner DJ, Fan X, Tseng CW, Liu GY, Badiou C, Etienne J, Lina G, Matthay MA, DeLeo FR, Chambers HF. 2010. Polymorphonuclear leukocytes mediate Staphylococcus aureus Panton-Valentine leukocidin-induced lung inflammation and injury. Proc. Natl. Acad. Sci. U. S. A. 107:5587-5592. http://dx.doi.org/10.1073/pnas.0912403107.
11. Gillet Y, Vanhems P, Lina G, Bes M, Vandenesch F, Floret D, Etienne J. 2007. Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidin. Clin. Infect. Dis. 45:315-321. http://dx.doi.org/10.1086/519263. (Pubitemid 47101027)
12. David MZ, Daum RS. 2010. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin. Microbiol. Rev. 23:616-687. http://dx.doi.org/10.1128/CMR.00081- 09.
13. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak JM, Talan DA, Chambers HF. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin. Infect. Dis. 52:e18-55. http://dx.doi.org/10.1093/ cid/ciq146.
14. McDougal LK, Fosheim GE, Nicholson A, Bulens SN, Limbago BM, Shearer JE, Summers AO, Patel JB. 2010. Emergence of resistance among USA300 methicillin-resistant Staphylococcus aureus isolates causing invasive disease in the United States. Antimicrob. Agents Chemother. 54:3804-3811. http://dx.doi.org/10.1128/AAC.00351-10.
15. Jacobs MR, Good CE, Windau AR, Bajaksouzian S, Biek D, Critchley IA, Sader HS, Jones RN. 2010. Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States. Antimicrob. Agents Chemother. 54:2716-2719. http://dx.doi.org/10.1128/AAC.01797-09.
16. McGee L, Biek D, Ge Y, Klugman M, du Plessis M, Smith AM, Beall B, Whitney CG, Klugman KP. 2009. In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 53:552-556. http://dx.doi.org/10.1128/ AAC.01324-08.
17. Mushtaq S, Warner M, Ge Y, Kaniga K, Livermore DM. 2007. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J. Antimicrob. Chemother. 60:300-311. http://dx.doi.org/10.1093/jac/dkm150. (Pubitemid 47243878)
18. Sader HS, Fritsche TR, Jones RN. 2008. Antimicrobial activities of ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 52:1153-1155. http://dx.doi.org/10.1128/AAC.01351-07. (Pubitemid 351358404)
19. Saravolatz L, Pawlak J, Johnson L. 2010. In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 54:3027-3030. http://dx.doi.org/10.1128/ AAC.01516-09.
20. Zhanel GG, Rossnagel E, Nichol K, Cox L, Karlowsky JA, Zelenitsky S, Noreddin AM, Hoban DJ. 2011. Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus using an in vitro model. J. Antimicrob. Chemother. 66:1301-1305. http://dx.doi.org/10.1093/ jac/dkr110.
21. Forest Pharmaceuticals, Inc. 2012. Teflaro (ceftaroline fosamil) prescribing information. Forest Pharmaceuticals, Inc., St. Louis, MO.
22. AstraZeneca AB. 2012. Zinforo; summary of product characteristics. AstraZeneca AB, Sodertalje, Sweden.
23. Löffler B, Hussain M, Grundmeier M, Brück M, Holzinger D, Varga G, Roth J, Kahl BC, Proctor RA, Peters G. 2010. Staphylococcus aureus Panton-Valentine leukocidin is a very potent cytotoxic factor for human neutrophils. PLoS Pathog. 6:e1000715. http://dx.doi.org/10.1371/journal.ppat. 1000715.
24. Lipinska U, Hermans K, Meulemans L, Dumitrescu O, Badiou C, Duchateau L, Haesebrouck F, Etienne J, Lina G. 2011. Panton-Valentine leukocidin does play a role in the early stage of Staphylococcus aureus skin infections: a rabbit model. PLoS One 6:e22864. http://dx.doi.org/10.1371/journal.pone.0022864.
25. Voyich JM, Otto M, Mathema B, Braughton KR, Whitney AR, Welty D, Long RD, Dorward DW, Gardner DJ, Lina G, Kreiswirth BN, DeLeo FR. 2006. Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease? J. Infect. Dis. 194:1761-1770. http://dx.doi.org/10.1086/509506. (Pubitemid 44902009)
26. Croisier-Bertin D, Piroth L, Charles P-E, Larribeau A, Biek D, Ge Y, Chavanet P. 2011. Ceftaroline versus ceftriaxone in a highly penicillin-resistant pneumococcal pneumonia rabbit model using simulated human dosing. Antimicrob. Agents Chemother. 55:3557-3563. http://dx.doi.org/10.1128/ AAC.01773-09.
27. Piroth L, Martin L, Coulon A, Lequeu C, Duong M, Buisson M, Portier H, Chavanet P. 1999. Development of a new experimental model of penicillin-resistant Streptococcus pneumoniae pneumonia and amoxicillin treatment by reproducing human pharmacokinetics. Antimicrob. Agents Chemother. 43:2484-2492. (Pubitemid 29471232)
28. Badiou C, Dumitrescu O, George N, Forbes AR, Drougka E, Chan KS, Ramdani-Bouguessa N, Meugnier H, Bes M, Vandenesch F, Etienne J, Hsu LY, Tazir M, Spiliopoulou I, Nimmo GR, Hulten KG, Lina G. 2010. Rapid detection of Staphylococcus aureus Panton-Valentine leukocidin in clinical specimens by enzyme-linked immunosorbent assay and immunochromatographic tests. J. Clin. Microbiol. 48:1384-1390. http://dx.doi.org/10.1128/JCM.02274-09.
29. Dumitrescu O, Choudhury P, Boisset S, Badiou C, Bes M, Benito Y, Wolz C, Vandenesch F, Etienne J, Cheung AL, Bowden MG, Lina G. 2011. Beta-lactams interfering with PBP1 induce Panton-Valentine leukocidin expression by triggering sarA and rot global regulators of Staphylococcus aureus. Antimicrob. Agents Chemother. 55:3261-3271. http://dx.doi.org/10.1128/AAC.01401-10.
30. Pfaffl MW, Horgan GW, Dempfle L. 2002. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 30:e36. http://dx.doi.org/10.1093/ nar/30.9.e36.
31. Kosowska-Shick K, McGhee PL, Appelbaum PC. 2010. Affinity of ceftaroline and other β-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob. Agents Chemother. 54:1670-1677. http://dx.doi.org/10.1128/AAC.00019-10.
32. Moisan H, Pruneau M, Malouin F. 2010. Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae. J. Antimicrob. Chemother. 65:713-716. http://dx.doi.org/10.1093/jac/ dkp503.
33. Jacqueline C, Amador G, Caillon J, Le Mabecque V, Batard E, Miègeville AF, Biek D, Ge Y, Potel G, Hamel A. 2010. Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis. J. Antimicrob. Chemother. 65:1749-1752. http://dx.doi.org/10.1093/jac/dkq193.
34. Jacqueline C, Caillon J, Le Mabecque V, Miègeville AF, Hamel A, Bugnon D, Ge JY, Potel G. 2007. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob. Agents Chemother. 51:3397-3400. http://dx.doi.org/10.1128/AAC.01242-06. (Pubitemid 350067563)
35. Bhalodi AA, Crandon JL, Biek D, Nicolau DP. 2012. Efficacy of ceftaroline fosamil in a staphylococcal murine pneumonia model. Antimicrob. Agents Chemother. 56:6160-6165. http://dx.doi.org/10.1128/AAC.01078-12.
36. Diep BA, Afasizheva A, Le HN, Kajikawa O, Matute-Bello G, Tkaczyk C, Sellman B, Badiou C, Lina G, Chambers HF. 12 April 2013. Effects of linezolid on suppressing in vivo production of staphylococcal toxins and improving survival outcomes in a rabbit model of methicillin-resistant Staphylococcus aureus necrotizing pneumonia. J. Infect. Dis. http://dx.doi.org/10.1093/infdis/jit129.
37. Mohapatra TM, Shrestha B, Pokhrel BM. 2009. Constitutive and inducible clindamycin resistance in Staphylococcus aureus and their association with meticillin-resistant S. aureus (MRSA): experience from a tertiary care hospital in Nepal. Int. J. Antimicrob. Agents 33:187-189. http://dx.doi.org/10.1016/j. ijantimicag.2008.08.009.
38. Docobo-Pérez F, López-Rojas R, Domínguez-Herrera J, Jiménez-Mejias ME, Pichardo C, Ibáñez-Martínez J, Pachón J. 2012. Efficacy of linezolid versus a pharmacodynamically optimized vancomycin therapy in an experimental pneumonia model caused by methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 67:1961-1967. http://dx.doi.org/10.1093/jac/dks142.
39. Martinez-Olondris P, Rigol M, Soy D, Guerrero L, Agusti C, Quera MA, Li Bassi G, Esperatti M, Luque N, Liapikou M, Filella X, Marco F, de la Bellacasa JP, Torres A. 2012. Efficacy of linezolid compared to vancomycin in an experimental model of pneumonia induced by methicillin-resistant Staphylococcus aureus in ventilated pigs. Crit. Care Med. 40:162-168. http://dx.doi.org/10. 1097/CCM.0b013e31822d74a2.
40. Vidaillac C, Leonard SN, Rybak MJ. 2009. In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model. Antimicrob. Agents Chemother. 53:4712-4717. http://dx.doi.org/10.1128/AAC.00636-09.
41. Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, McGee WT, Reisman A, Chastre J. 2012. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin. Infect. Dis. 54:621-629. http://dx.doi.org/10.1093/cid/cir895.
42. Deresinski S. 2007. Counterpoint: vancomycin and Staphylococcus aureus - an antibiotic enters obsolescence. Clin. Infect. Dis. 44:1543-1548. http://dx.doi.org/10.1086/518452. (Pubitemid 46871499)
43. Kollef MH. 2007. Limitations of vancomycin in the management of resistant staphylococcal infections. Clin. Infect. Dis. 45(Suppl 3): S191-S195. http://dx.doi.org/10.1086/519470. (Pubitemid 47378906)